Skip to main content
. 2020 Aug 27;2020:8359860. doi: 10.1155/2020/8359860

Figure 5.

Figure 5

Silencing PRDX2 inhibits NSCLC cell proliferation in vivo. (a) PRDX2-knockdown or control A549 cells were subcutaneously injected into left axilla. The tumor volume (b) and tumor weights (c) in control group and PRDX2-knockdown were calculated. (d) The expression of Ki-67 and PCNA in control group and PRDX2-knockdown group was performed by immunohistochemistry assay. Scale bar = 50 μm in (d). ∗P < 0.05.